Analyst Ratings For Cerus Corporation (NASDAQ:CERS)
Today, Cantor Fitzgerald reiterated its Buy rating on Cerus Corporation (NASDAQ:CERS) with a price target of $9.00.
There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Cerus Corporation (NASDAQ:CERS) is Buy with a consensus target price of $8.00 per share, a potential 12.83% upside.
Some recent analyst ratings include
- 10/3/2018-Cerus Corporation (NASDAQ:CERS) had its Buy rating reiterated by Cantor Fitzgerald with a $9.00 price target
- 5/9/2018-Cerus Corporation (NASDAQ:CERS) had its Hold rating reiterated by BTIG Research
- 12/1/2017-Cerus Corporation (NASDAQ:CERS) had its Buy rating reiterated by Robert W. Baird with a $5.00 price target
Recent Insider Trading Activity For Cerus Corporation (NASDAQ:CERS)
Cerus Corporation (NASDAQ:CERS) has insider ownership of 6.80% and institutional ownership of 59.76%.
- On 9/10/2018 Kevin Dennis Green, CFO, sold 2,783 with an average share price of $7.24 per share and the total transaction amounting to $20,148.92.
- On 8/28/2018 Kevin Dennis Green, CFO, sold 50,000 with an average share price of $7.50 per share and the total transaction amounting to $375,000.00.
- On 8/14/2018 Richard J Benjamin, Insider, sold 35,416 with an average share price of $7.20 per share and the total transaction amounting to $254,995.20.
- On 8/10/2018 Kevin Dennis Green, CFO, sold 2,783 with an average share price of $6.96 per share and the total transaction amounting to $19,369.68.
- On 6/8/2018 Gail Schulze, Director, sold 52,500 with an average share price of $6.65 per share and the total transaction amounting to $349,125.00.
- On 6/5/2018 Carol Moore, SVP, sold 75,000 with an average share price of $6.72 per share and the total transaction amounting to $504,000.00.
- On 5/18/2018 Timothy B Anderson, Director, sold 23,000 with an average share price of $6.65 per share and the total transaction amounting to $152,950.00.
About Cerus Corporation (NASDAQ:CERS)
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Recent Trading Activity for Cerus Corporation (NASDAQ:CERS)
Shares of Cerus Corporation closed the previous trading session at 7,09 −0,070 0,98 % with shares trading hands.